{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:49:37Z","timestamp":1790732977502,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,11]]},"DOI":"10.7759\/cureus.110655","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:47:16Z","timestamp":1781178436000},"source":"Crossref","is-referenced-by-count":1,"title":["Risk Factors and Clinical Predictors of Drug-Induced Hepatotoxicity in Patients Receiving First-Line Anti-tuberculosis Therapy"],"prefix":"10.7759","author":[{"given":"Hammad","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momna","family":"Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Aftab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Allah","family":"Diwaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Haider","family":"Farooq Sherazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Younas","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Wasil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziadullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naqeeb","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeeb","family":"Ullah Noraiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Hepatotoxicity associated with anti-tuberculosis medications: analyzing mechanisms, risk factors, and strategies for prevention and management","volume":"1","author":"Zade D","year":"2024","unstructured":"Zade D. Hepatotoxicity associated with anti-tuberculosis medications: analyzing mechanisms, risk factors, and strategies for prevention and management. J Drug Deliv Biotherapeutics. 2024, 1:","journal-title":"J Drug Deliv Biotherapeutics"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-74786-2_52-1","article-title":"Tuberculosis management in developing countries","author":"Al-Worafi YM","year":"2023","unstructured":"Al-Worafi YM. Tuberculosis management in developing countries. Handbook of Medical and Health Sciences in Developing Countries: Education, Practice, and Research. Al-Worafi YM (ed): Springer, Cham, Switzerland; 2023. 1-40. 10.1007\/978-3-030-74786-2_52-1"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2399074","article-title":"Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis","volume":"23","author":"Lewis JH","year":"2024","unstructured":"Lewis JH, Korkmaz SY, Rizk CA, Copeland MJ. Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis. Expert Opin Drug Saf. 2024, 23:1093-107. 10.1080\/14740338.2024.2399074","journal-title":"Expert Opin Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/livers6020019","article-title":"Antitubercular drug-induced liver injury in the treatment of tuberculous lymphadenitis: a comprehensive review","volume":"6","author":"Skuhala T","year":"2026","unstructured":"Skuhala T, Dragobratovi\u0107 A, Marinkovi\u0107 L, Ramljak K, Rimac M, Paveli\u0107 A, Lepej SZ. Antitubercular drug-induced liver injury in the treatment of tuberculous lymphadenitis: a comprehensive review. Livers. 2026, 6:19. 10.3390\/livers6020019","journal-title":"Livers"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-015-1473-1","article-title":"Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity","volume":"89","author":"Chen R","year":"2015","unstructured":"Chen R, Wang J, Zhang Y, Tang S, Zhan S. Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity. Arch Toxicol. 2015, 89:883-97. 10.1007\/s00204-015-1473-1","journal-title":"Arch Toxicol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/15376516.2025.2554918","article-title":"Unveiling the molecular toxicity of isoniazid and rifampicin in tuberculosis therapy: emerging insights and therapeutic strategies","volume":"35","author":"Shivaji P","year":"2025","unstructured":"Shivaji P, Prince SE. Unveiling the molecular toxicity of isoniazid and rifampicin in tuberculosis therapy: emerging insights and therapeutic strategies. Toxicol Mech Methods. 2025, 35:1239-70. 10.1080\/15376516.2025.2554918","journal-title":"Toxicol Mech Methods"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2007.00129.x","article-title":"Potentiation of isoniazid-induced liver toxicity by rifampicin in a combinational therapy of antitubercular drugs (rifampicin, isoniazid and pyrazinamide) in Wistar rats: a toxicity profile study","volume":"37","author":"Tasduq SA","year":"2007","unstructured":"Tasduq SA, Kaiser P, Sharma SC, Johri RK. Potentiation of isoniazid-induced liver toxicity by rifampicin in a combinational therapy of antitubercular drugs (rifampicin, isoniazid and pyrazinamide) in Wistar rats: a toxicity profile study. Hepatol Res. 2007, 37:845-53. 10.1111\/j.1872-034X.2007.00129.x","journal-title":"Hepatol Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v13.i11.1688","article-title":"Abnormal liver enzymes: a review for clinicians","volume":"13","author":"Kalas MA","year":"2021","unstructured":"Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: a review for clinicians. World J Hepatol. 2021, 13:1688-98. 10.4254\/wjh.v13.i11.1688","journal-title":"World J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12370","article-title":"Influence of sex in alcohol-related liver disease: pre-clinical and clinical settings","volume":"11","author":"Bizzaro D","year":"2023","unstructured":"Bizzaro D, Becchetti C, Trapani S, et al.. Influence of sex in alcohol-related liver disease: pre-clinical and clinical settings. United European Gastroenterol J. 2023, 11:218-27. 10.1002\/ueg2.12370","journal-title":"United European Gastroenterol J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2016.1271807","article-title":"Drug metabolism and liver disease: a drug-gene-environment interaction","volume":"49","author":"Zgheib NK","year":"2017","unstructured":"Zgheib NK, Branch RA. Drug metabolism and liver disease: a drug-gene-environment interaction. Drug Metab Rev. 2017, 49:35-55. 10.1080\/03602532.2016.1271807","journal-title":"Drug Metab Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286306","article-title":"Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?","volume":"18","author":"D Freire I","year":"2023","unstructured":"D Freire I, L Fielding K, A J Moore D. Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?. PLoS One. 2023, 18:e0286306. 10.1371\/journal.pone.0286306","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-019-4872-1","article-title":"Drug-induced hepatotoxicity among TB\/HIV co-infected patients in a referral hospital, Ethiopia","volume":"13","author":"Zeleke A","year":"2020","unstructured":"Zeleke A, Misiker B, Yesuf TA. Drug-induced hepatotoxicity among TB\/HIV co-infected patients in a referral hospital, Ethiopia. BMC Res Notes. 2020, 13:2. 10.1186\/s13104-019-4872-1","journal-title":"BMC Res Notes"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.26719\/emhj.23.050","article-title":"Observational study and literature review of the use of camel urine for treatment of cancer patients","volume":"29","author":"Al Zahrani A","year":"2023","unstructured":"Al Zahrani A, Alfakeeh A, Alghareeb W, Bakhribah H, Basulaiman B, Alsuhail A. Observational study and literature review of the use of camel urine for treatment of cancer patients. East Mediterr Health J. 2023, 29:3.","journal-title":"East Mediterr Health J"},{"key":"ref14","article-title":"Physical status: the use of and interpretation of anthropometry, report of a WHO expert committee","year":"1995","unstructured":"Physical Status. The Use of and Interpretation of Anthropometry, Report of a WHO Expert Committee. World Health Organization, Geneva, Switzerland; 1995. https:\/\/www.who.int\/publications\/i\/item\/9241208546."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann A","year":"2008","unstructured":"Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008, 23:192-202. 10.1111\/j.1440-1746.2007.05207.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-024-01643-w","article-title":"Incidence and risk factors of antituberculosis drug-induced liver injury in India: a systematic review and meta-analysis","volume":"44","author":"Kumar R","year":"2025","unstructured":"Kumar R, Kumar A, Patel R, Prakash SS, Kumar S, Surya H, Marrapu S. Incidence and risk factors of antituberculosis drug-induced liver injury in India: a systematic review and meta-analysis. Indian J Gastroenterol. 2025, 44:35-46. 10.1007\/s12664-024-01643-w","journal-title":"Indian J Gastroenterol"},{"key":"ref17","article-title":"Common risk factors for the development of anti tuberculosis treatment induced hepatotoxicity","volume":"26","author":"Abbasi MA","year":"2014","unstructured":"Abbasi MA, Ahmed N, Suleman A, Zaman H, Tariq S, Anwar SA, Khan N. Common risk factors for the development of anti tuberculosis treatment induced hepatotoxicity. J Ayub Med Coll Abbottabad. 2014, 26:384-8.","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"ref18","article-title":"Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity","volume":"132","author":"Singla R","year":"2010","unstructured":"Singla R, Sharma SK, Mohan A, et al.. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian Journal of Medical Research. 2010, 132:81-6.","journal-title":"Indian Journal of Medical Research"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122786","article-title":"Sex differences in liver toxicity-do female and male human primary hepatocytes react differently to toxicants in vitro?","volume":"10","author":"Mennecozzi M","year":"2015","unstructured":"Mennecozzi M, Landesmann B, Palosaari T, Harris G, Whelan M. Sex differences in liver toxicity-do female and male human primary hepatocytes react differently to toxicants in vitro?. PLoS One. 2015, 10:e0122786. 10.1371\/journal.pone.0122786","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.2.132","article-title":"Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study","volume":"51","author":"Pande JN","year":"1996","unstructured":"Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax. 1996, 51:132-6. 10.1136\/thx.51.2.132","journal-title":"Thorax"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3329\/bjch.v46i1.70010","article-title":"Anti-tuberculosis drug-induced hepatitis","volume":"46","author":"Karim AB","year":"2022","unstructured":"Karim AB, Musabbir N. Anti-tuberculosis drug-induced hepatitis. Bangladesh J Child Health. 2022, 46:23-7. 10.3329\/bjch.v46i1.70010","journal-title":"Bangladesh J Child Health"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad422","article-title":"Metabolic disorders are associated with drug-induced liver injury during antituberculosis treatment: a multicenter prospective observational cohort study in Korea","volume":"10","author":"Lim J","year":"2023","unstructured":"Lim J, Kim JS, Kim HW, et al.. Metabolic disorders are associated with drug-induced liver injury during antituberculosis treatment: a multicenter prospective observational cohort study in Korea. Open Forum Infect Dis. 2023, 10:ofad422. 10.1093\/ofid\/ofad422","journal-title":"Open Forum Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/482736-risk-factors-and-clinical-predictors-of-drug-induced-hepatotoxicity-in-patients-receiving-first-line-anti-tuberculosis-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:47:17Z","timestamp":1781178437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/482736-risk-factors-and-clinical-predictors-of-drug-induced-hepatotoxicity-in-patients-receiving-first-line-anti-tuberculosis-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.110655","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}